Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 797 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Celgene Clear all
Completed Phase 2 Interventional Results available

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

NCT02716038
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
MPDL3280A, Carboplatin, Nab-paclitaxel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies

NCT00890955
View directory record Official record
Conditions
Lung Cancer
Interventions
Amrubicin, Cyclophosphamide
Drug
Lead sponsor
Lawrence Einhorn
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Springdale, Arkansas • Newark, Delaware • Galesburg, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

NCT00569010
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Azacitidine, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib

NCT00667147
View directory record Official record
Conditions
Solid Tumors
Interventions
Weekly Abraxane and Daily Vandetanib, Abraxane every three weeks and daily vandetanib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 15, 2026, 1:22 AM EDT
Not listed Phase 2 Interventional

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

NCT00777673
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Drug
Lead sponsor
University of Tennessee Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

NCT00098865
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Neuroblastoma
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 15, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

NCT00209014
View directory record Official record
Conditions
B-Cell Lymphoma, Hodgkin's Disease
Interventions
Thalidomide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Oct 15, 2026, 1:22 AM EDT
Recruiting Phase 1 Interventional

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

NCT06348108
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy
Biological · Drug · Procedure
Lead sponsor
Alfred Chung, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 3 Interventional

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

NCT00083876
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2010 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

NCT04800315
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
62
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397
View directory record Official record
Conditions
Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
Interventions
CC-223
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

NCT04573582
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

NCT00044382
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
CC-5013
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Not applicable Interventional

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

NCT00308178
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

NCT02521714
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 15, 2026, 1:22 AM EDT
Withdrawn Phase 2 Interventional

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

NCT03881735
View directory record Official record
Conditions
Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Enasidenib, Hematopoietic Cell Transplantation
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Buffalo, New York • East Hills, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

NCT01274533
View directory record Official record
Conditions
Adult T Cell Leukemia/Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

NCT02531126
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Mission Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants

NCT04718636
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami, Florida • Marlton, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01497093
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 15, 2026, 1:22 AM EDT
Terminated No phase listed Observational

Connect® Myeloid Disease Registry

NCT01688011
View directory record Official record
Conditions
Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
155
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 15, 2026, 1:22 AM EDT
Terminated Phase 4 Interventional

Use of Thalidomide in Chronic Uveitis

NCT00314665
View directory record Official record
Conditions
Uveitis
Interventions
Thalidomide
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

NCT00091624
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 15, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CC-10004 for Prurigo Nodularis

NCT00869089
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
CC-10004
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 15, 2026, 1:22 AM EDT